Wellington Management Group LLP boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 32.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,726,613 shares of the biotechnology company's stock after purchasing an additional 665,087 shares during the quarter. Wellington Management Group LLP owned about 2.85% of Sarepta Therapeutics worth $340,527,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also bought and sold shares of SRPT. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter worth about $31,000. Huntington National Bank boosted its stake in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after buying an additional 175 shares in the last quarter. Nkcfo LLC purchased a new stake in Sarepta Therapeutics in the second quarter worth approximately $43,000. Riggs Asset Managment Co. Inc. grew its position in Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after acquiring an additional 75 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 197 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
SRPT has been the subject of a number of research reports. HC Wainwright cut their price objective on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating for the company in a research note on Tuesday, December 3rd. William Blair raised Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They issued a "buy" rating and a $165.00 target price for the company. Piper Sandler dropped their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. Finally, Guggenheim lifted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $175.55.
View Our Latest Analysis on Sarepta Therapeutics
Sarepta Therapeutics Stock Performance
NASDAQ:SRPT traded up $1.89 during mid-day trading on Friday, reaching $128.17. The company's stock had a trading volume of 619,477 shares, compared to its average volume of 1,329,769. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a market cap of $12.24 billion, a P/E ratio of 102.54 and a beta of 0.77. The firm's fifty day moving average price is $122.71 and its two-hundred day moving average price is $131.33. Sarepta Therapeutics, Inc. has a 12-month low of $85.61 and a 12-month high of $173.25.
Insider Transactions at Sarepta Therapeutics
In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm's stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company's stock, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 7.70% of the company's stock.
Sarepta Therapeutics Profile
(
Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Read More
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.